Cannara Biotech EBIT

The latest EBIT for LOVFF is $19M as of May 2026. That compares with $21M in the prior-year period — down 10.2% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Cannara Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, LOVFF's EBIT moved from $21M to $19M — a 10.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cannara Biotech's operating scale or balance-sheet position.

Against its sector companies, LOVFF currently prints $19M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Cannara Biotech's growth, margins, and balance sheet.

A EBIT figure of $19M for LOVFF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting LOVFF's EBIT ($19M), review year-over-year change from $21M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.